Bias‐corrected estimates of effects of PSA screening decisions on the risk of prostate cancer diagnosis and death: Analysis of the Finnish randomized study of screening for prostate cancer
- 17 January 2019
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 145 (3) , 632-638
Abstract
More information is needed about effects of prostate‐specific antigen (PSA) screening for informed decision making. The objective of our study is to evaluate the effects of an implemented screening decision on the risk of prostate cancer (PC) diagnosis and PC death. In a randomized trial, 31,867 Finnish men aged 55–67 years were allocated to the screening arm and 48,282 to the control arm during 1996–1999. Two to three screening rounds were offered to the screening arm with a PSA cut‐off of 4.0 ng/ml. A counterfactual exclusion method was used to adjust for the effects of screening noncompliance and PSA contamination on risk of PC death and PC incidence by prognostic group at 15 years of follow up. After correcting for noncompliance and contamination, PSA screening led to 32.4 (95% CI 26.4, 38.6) more PC diagnoses per 1,000 men after 15 years and 1.4 (95% CI 0.0, 2.8) fewer PC deaths compared to the control arm. The corresponding results of an intention‐to‐screen analysis were 16.5 (95% CI 12.3, 20.7) and 0.8 (95% CI 0.5, 2.0), respectively. These results can be used for patient counseling in informed decision making about PC screening. A limitation of the study was the lack of comprehensive data on contamination.Keywords
Funding Information
- Research Council of Finland (260931)
- Syöpäjärjestöt
- Research Council of Finland (#260931)
- Syöpäjärjestöt
This publication has 18 references indexed in Scilit:
- Prostate-specific Antigen–Based Prostate Cancer Screening: Reduction of Prostate Cancer Mortality After Correction for Nonattendance and Contamination in the Rotterdam Section of the European Randomized Study of Screening for Prostate CancerEuropean Urology, 2014
- Early Detection of Prostate Cancer: AUA GuidelineJournal of Urology, 2013
- Prognostic G leason grade grouping: data based on the modified G leason scoring systemBJU International, 2013
- Shared decision making for prostate cancer screening: the results of a combined analysis of two practice-based randomized controlled trialsBMC Medical Informatics and Decision Making, 2012
- Prostate Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality Results after 13 Years of Follow-upJNCI: Journal of the National Cancer Institute, 2012
- Difference in Willingness-to-pay for Prostate Cancer Screening Between Ill-informed and Well-informed Men: A Contingent Valuation SurveyUrology, 2011
- American Cancer Society Guideline for the Early Detection of Prostate Cancer: Update 2010CA: A Cancer Journal for Clinicians, 2010
- Estimates of cancer incidence and mortality in Europe in 2008European Journal of Cancer, 2010
- Prostate Cancer Mortality Reduction by Prostate-Specific Antigen–Based Screening Adjusted for Nonattendance and Contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC)European Urology, 2009
- The Finnish trial of prostate cancer screening: where are we now?BJU International, 2003